According to Zacks, “SIGA Technologies Inc. is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents and vaccines to fight potential biowarfare pathogens. With broad technology platforms in both vaccines and antibiotics, SIGA’s product development programs emphasize the increasingly serious problem of drug resistant bacteria. In addition to smallpox, SIGA has antiviral programs targeting other Category A pathogens, including arenaviruses, dengue virus, and the filoviruses. “
Separately, TheStreet raised SIGA Technologies from a “c+” rating to a “b” rating in a report on Monday, April 18th.
SIGA Technologies (NASDAQ:SIGA – Get Rating) last posted its quarterly earnings results on Thursday, March 3rd. The company reported $0.98 EPS for the quarter. SIGA Technologies had a return on equity of 49.45% and a net margin of 50.13%. The firm had revenue of $115.40 million during the quarter. As a group, sell-side analysts forecast that SIGA Technologies will post 0.67 EPS for the current year.
Hedge funds have recently bought and sold shares of the business. Metropolitan Life Insurance Co NY acquired a new stake in SIGA Technologies during the third quarter worth $90,000. GSA Capital Partners LLP acquired a new stake in SIGA Technologies during the third quarter worth $101,000. SG Americas Securities LLC purchased a new position in shares of SIGA Technologies during the third quarter worth $252,000. Russell Investments Group Ltd. purchased a new position in shares of SIGA Technologies during the third quarter worth $3,458,000. Finally, Barclays PLC boosted its position in shares of SIGA Technologies by 214.0% during the third quarter. Barclays PLC now owns 23,460 shares of the company’s stock worth $174,000 after buying an additional 15,989 shares during the period. 34.52% of the stock is owned by institutional investors.
About SIGA Technologies (Get Rating)
SIGA Technologies, Inc, a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats.
- Get a free copy of the StockNews.com research report on SIGA Technologies (SIGA)
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related companies with MarketBeat.com's FREE daily email newsletter.